RECEIVED CENTRAL FAX CENTER

PAGE 01/07

NOV 1 8 2005

PTO/SB/21 (02-04) Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. Application Number 10/714,452 Filing Date TRANSMITTAL 11/14/2003 FORM First Named Inventor BAMDAD, R. Shoshana Art Unit 1814 (to be used for all correspondence after initial filing) Examiner Name Phyllis G. Spivack Attorney Docket Number M1015.70046U\$01 Total Number of Pages In This Submission (Check all that apply) **ENCLOSURES** After Allowance communication to Technology Center (TC) Fee Transmittal Form Drawing(s) Appeal Communication to Board Licensing-related Papers of Appeals and Interferences Fee Attached Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) Petition Amendment/Reply Petition to Convert to a Proprietary Information Provisional Application After Final Power of Attorney, Revocation Status Letter Affidavits/declaration(s) Change of Correspondence Address Other Enclosure(s) (please Terminal Disclaimer Identify below): **Extension of Time Request** PTO/SB/08A, PTO/SB/08B, and Credit Card Request for Refund Express Abandonment Request Payment Form for \$180 CD, Number of CD(s) Information Disclosure Statement Remarks Certified Copy of Priority No copy of the references is included in this submission. Document(s) This correspondence is being facsimile transmitted to (571) 273-8300. Response to Missing Parts/ Incomplete Application *Only 4 of the 7 pages were previously transmitted via facsimile. Due to this error, we are resending the full enclosure with this transmittal. PLEASE DO NOT CHARGE THE AMOUNT Response to Missing Parts under 37 CFR 1.52 or 1.53 OF \$180 TWICE FOR THIS SUBMISSION. SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Firm Joseph Hyosuk Kim, Ph.D. Reg. No. 41,425 Individual name JHK Law Sianeture Date November 18, 2005 CERTIFICATE OF TRANSMISSION/MAILING I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below. Typed or printed name Harry Sung Lee عد Date November 18, 2005 Signature

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

RECEIVED CENTRAL FAX CENTER

NOV 1 8 2005

PATENT

Docket No. M1015.70046US01

I hereby certify that on November 18, 2005, which is the date I am signing this certificate, I am transmitting this correspondence and all identified attachments to (571) 273-8300, Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

8182498277

Harry Lee

Applicant: BAMDAD, B. Shoshana

Filed: 11/14/2003
Confirmation No.: 9378
Title: ENDOSTATIN-LIKE
ANGIOGENESIS INHIBITION
Examiner: Phyllis G. Spivack

Art Unit: 1614

Serial No.: 10/714,452

Attorney Docket No.: M1015.70046US01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with 37 C.F.R. § 1.56, the references listed below and on the attached forms PTO/SB/08A and PTO/SB/08B (substitutes for form 1449/PTO) are being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application. The filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made (37 C.F.R. § 1.97(g)), as an admission that the information cited is, or is considered to be, material to patentability, or that no other material information exists. The filing of this Information Disclosure Statement shall not be construed as an admission against interest in any manner. Copies of the cited documents are enclosed.

English Language Documents:

US 2002/0042074 A1, BAMDA	Detal., April 11, 2002
US 2002/0086443 A1, BAMDZ	DJ July 4: 2002: State of the little of the
US 2002/0098526 A1, BAMDA	D, July 25, 2002

Application No. 10/714,452

US 2002/0156112 A1, BAMDAD et al., October 24, 2002
US 2002/0164611 A1, BAMDAD et al., November 7, 2002
GB 1,153,113 A, CHUGALSEIYAKU KABUSHIKI KAISHA MW 21, 1969
WO 97/48409 A.J., SLUSHER et al., December 24, 1997.
CINATL et al., "Cytotoxicity of L-Cycloserme Against Homan Neuroblastoma and Medulioblastoma Cells is Associated with the Suppression of Ganglioside Expression", Articancer Research (1999), 16(6B), 5349-5354
GAGLIARDI et al., "Inhibition of Angiogenesis by Sutamin", Camber Research (1992), 52(18): 5073-5075
GAGLIARDI et al., "Inhibition of Angiogenesis by Suramin and its Analogues (Neovascularization Tumor Vasculature", Dissertation Abstract
KREGE, "Indications for Topical Treatment for Superficial Bladder Cancer", Urologue Ausgabe A (1992), 31(4): 201-202
O'REILLY et al., "Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth"; Cell (1997), 88: 277-285

JHK LAW

It is respectfully requested that the Examiner indicate consideration of the cited references by returning copies of the attached forms PTO/SB/08A and PTO/SB/08B (substitutes for form 1449/PTO) with initials or other appropriate marks, and that the references be made of record as cited references in the application.

All of the references listed above have been cited by the Examiner or submitted by Applicant to the USPTO with an information disclosure statement in connection with the parent application number 10/003,681 filed November 15, 2001. Therefore, it is believed that all of the references can be found in the files for application number 10/003,681 and no copy of the references is included in this submission.

The Commissioner is authorized to charge JHK Law's Deposit Account No. 502486 for any fees required under 37 CFR §§ 1.16 and 1.17 that are not covered, in whole or in part, by a credit card payment form enclosed herewith and to credit any overpayment to said Deposit Account No. 502486.

BEST AVAILABLE COPY

Docket No. M1015.70046U\$01

8182498277

Application No. 10/714,452

Respectfully submitted,

Hammeler, Reg. M. 56, 814

November 18, 2005

Date

Joseph Hyosuk Kim, Ph.D.

Reg. No. 41,425

Attorney for Applicants

JHK Law

P.O. Box 1078

La Canada, CA 91012-1078

Telephone: (818) 249-8177 Facsimile: (818) 249-8277

PTO/SB/08A (08-03)

Attorney Docket Number M1015.70046US01

Approved for use through 07/31/2006. OMB 0851-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Substitute for form 1449/PTO Application Number 10/714,452 11/14/2003 Filing Date INFORMATION DISCLOSURE First Named Inventor BAMDAD, R. Shoshana STATEMENT BY APPLICANT Art Unit 1614 (Use as many shoots as necessary) Phyllis G. Spivack **Examiner Name**

			U. S. PATENT	DOCUMENTS	
Examiner Inițials*	Cite No. ³	Document Number Number-Kind Code ^{2 of Incom)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages of Relevant Figures Appear
	A1	US- 2002/0042074 A1	04-11-2002	BAMDAD et al.	whole document
	A2	US- 2002/0086443 A1	07-04-2002	BAMDAD	whole document
	A3	US- 2002/0098526 A1	07-25-2002	BAMDAD	whole document
	A4	US- 2002/0156112 A1	10-24-2002	BAMDAD et al.	whole document
	A5	US- 2002/0164611 A1	11-07-2002	BAMDAD et al.	whole document
		US-			
		US-			
-		US-			
		US-			
,		US-			
		U\$-			
		US-			
		U\$-			
		US-			
	1	us-			
	1	us-			

Cite No.	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pagea, Columns, Lines, Where Relevant Passages	Γ
	Country Code ³ TNumber ⁴ TGnd Code ³ (if known)	MM-DD-YYYY		Or Relevant Figures Appear	_
 B1	GB 1,153,113 A	05-21-1969	CHUGAI SEIYAKU KABUSHIKI KAISHA	whole document	Ĺ
B2	WO 97/48409 A1	12-24-1997	SLUSHER et al.	whole document	L
					L
 					Ļ
					L
				1	

Examiner Signature	Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609, Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). 'See Kinds Codes of considered. Include copy of this form with next communication to applicant. \[^1\text{Applicant's unique citation designation number (optional).}\[^2\text{See Kinds Codes of USPTO Patent Documents at \(\frac{\text{WW.uspto.gov}}{\text{or MPCP}}\) or MPEP 901.04. \[^3\text{Enter Office that issued the document, by the two-letter code (MPO Standard ST.3).}\[^3\text{For Japanese patent documents, the Indication of the year of the reign of the Emperor must precede the serial number of the patent document. \[^5\text{Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.18 if possible. \[^6\text{Applicant is to place a check.mark here if English language}\] Translation is attached.

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450.

To: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

8182498277

PTO/SB/08B (08-03)

Approved for use through 07/31/2005, OMS 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Subatitute for form 1449/PTO			. di 1000, 110 po/0011031	e required to respond to a collection of information unless it complete a valid Crisp control number. Complete if Known		
Substitute for form 1445/F10				Application Number	10/714,452	
INF	ORMATION	DIS	CLOSURE	Filing Date	11/14/2003	
STA	STATEMENT BY APPLICANT			First Named Inventor	BAMDAD, R. Shoshana	
				Art Unit	1614	
(Use as many sheets as necessary)			ecessary)	Examiner Name	Phyllis G. Spivack	
Sheet	1	of	1	Attorney Docket Number	M1015.70046US01	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	C1	CINATL et al., "Cytotoxicity of L-Cycloserine Against Human Neuroblastoma and Medulioblastoma Cells is Associated with the Suppression of Ganglioside Expression", Anticancer Research (1999), 16(6B): 5349-5354	
	C2	GAGLIARDI et al., "Inhibition of Angiogenesis by Suramin", Cancer Research (1992), 52(18): 5073-5075	
	СЗ	GAGLIARDI et al., "Inhibition of Angiogenesis by Suramin and its Analogues (Neovascularization, Tumor Vasculature", Dissertation Abstract	
	C4	KREGE, "Indications for Topical Treatment for Superficial Bladder Cancer", Urologue Ausgabe A (1992). 31(4): 201-202	
	C5	O'REILLY et al., "Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth", Cell (1997), 88: 277-285	
		·	

Examiner	Date	
Signature	Considered	

"EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Considered: include copy of this form with next committee on the applicant. It is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application from to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form endor suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.